Compare Abbott Laboratories (ABT) vs Charter Communications Inc (CHTR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Charter Communications Inc — how do they compare? Abbott Laboratories trades at $94.9 (market cap $166.94B), while Charter Communications Inc trades at $133.51 (market cap $16.97B). The key difference: Abbott Laboratories is far larger — about 9.8× Charter Communications Inc's market cap, and Abbott Laboratories pays a 2.63% dividend while Charter Communications Inc pays none. Which is the better fit depends on your goals.
| ABT | CHTR | |
|---|---|---|
Market Cap | $166.94B | $16.97B |
Sector | Health | Media |
52-Week High | $136.62 | $411.66 |
52-Week Low | $82.57 | $125.54 |
Enterprise Value | $193.69B | $113.28B |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Charter Communications (CHTR) trades at $138.02, up 0.6% on the day, with a bearish technical signal but deeply discounted valuation metrics including a P/E of 3.66 and EV/EBITDA of 5.32. Recent news highlights a potential mobile partnership with SpaceX, driving significant pre-market gains, while financials show stable revenue near $54.8B and improving operating cash flow to $16.08B in 2025.
The stock presents a high-risk, high-reward opportunity, with a consensus price target of $214 suggesting 55% upside, but faces headwinds from high debt, competitive pressures, and inconsistent earnings beats. Investor sentiment is mixed, balancing low valuation against operational challenges and leverage concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Charter Communications Inc
Charter is the product of the 2016 merger of three cable companies, each with a decades-long history in the business: Legacy Charter, Time Warner Cable, and Bright House Networks. The firm now holds networks capable of providing television, internet access, and phone services to roughly 54 million U.S. homes and businesses, around 40% of the country. Across this footprint, Charter serves 29 million residential and 2 million commercial customer accounts under the Spectrum brand, making it the second-largest U.S. cable company behind Comcast. The firm also owns, in whole or in part, sports and news networks, including Spectrum SportsNet (long-term local rights to Los Angeles Lakers games), SportsNet LA (Los Angeles Dodgers), SportsNet New York (New York Mets), and Spectrum News NY1.
Read more on CHTR →
